

## Article

# Association between Post-Diagnosis Particulate Matter Exposure Among 5-Year Cancer Survivors and Cardiovascular Disease Risk in Three Metropolitan Areas from South Korea

Seulggie Choi<sup>1</sup>, Kyae Hyung Kim<sup>2,3</sup>, Kyuwoong Kim<sup>1</sup>, Jooyoung Chang<sup>1</sup>, Sung Min Kim<sup>1</sup>, Seong Rae Kim<sup>4</sup>, Yoosun Cho<sup>2</sup>, Gyeongsil Lee<sup>2</sup>, Joung Sik Son<sup>2</sup>, Sang Min Park<sup>1,2,\*</sup>

<sup>1</sup> Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea

<sup>2</sup> Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea

<sup>3</sup> Institute for Public Health and Medical Service, Seoul National University Hospital, Seoul, South Korea

<sup>4</sup> College of Medicine, Seoul National University Hospital, Seoul, South Korea

Equal contributors: Seulggie Choi and Kyae Hyung Kim

\* Correspondence: Sang Min Park, MD, PhD, MPH

Department of Biomedical Sciences and Family Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, South Korea

Phone: 82-2-2072-3331

Fax: 82-2-766-3276

E-mail: [smpark.snuh@gmail.com](mailto:smpark.snuh@gmail.com)

**Abstract:** Cancer survivors are at an increased risk for cardiovascular disease (CVD). However, the association between particulate matter (PM) and CVD risk among cancer survivors (alive >5 years since diagnosis) is unclear. We investigated the risk of CVD among 40,899 cancer survivors within the Korean National Health Insurance Service database. Exposure to PM was determined by assessing yearly average PM levels obtained from the Air Korea database from 2008 to 2011. PMs with sizes <2.5 (PM<sub>2.5</sub>), <10 (PM<sub>10</sub>), or 2.5-10 (PM<sub>2.5-10</sub>)  $\mu\text{m}$  in diameter were compared, with each PM level exposure further divided into quintiles. Patients were followed up from January 2012 to date of CVD event, death, or December 2017, whichever came earliest. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CVD were calculated using Cox proportional hazards regression by PM exposure levels. Compared with cancer survivors in the lowest quintile of PM<sub>2.5</sub> exposure, those within the highest quintile had a greater risk for CVD (aHR 1.31, 95% CI 1.07-1.59). Conversely, increasing PM<sub>10</sub> and PM<sub>2.5-10</sub> levels were not associated with increased CVD risk (p for trend 0.078 and 0.361, respectively). Cancer survivors who reduce PM<sub>2.5</sub> exposure may reduce their risk of developing CVD.

**Keywords:** cardiovascular disease; particulate matter; cancer survivor; metropolitan area

## 1. Introduction

With the increasing incidence and the improved survival of patients with cancer, the number of cancer survivors is rapidly increasing in Korea. In 2016, 229,180 Koreans were newly diagnosed with cancer, while 78,194 died from cancer. The recent 5-year relative survival rate for cancer patients in Korea was 70.6% which was similar to that reported in the US of 67.1% [1,2]. Nearly a million people in Korea have survived for more than 5 years after their cancer diagnosis compared to over 11 million in the US [3,4]. Mortality from primary cancers accounts for up to 38.0% of all-cause mortality among cancer patients, while cardiovascular diseases (CVD) accounts for 11.3% [5]. Cardiovascular risk among these patients is as a consequence of the cardiotoxicity of treatment, biological mechanisms

such as inflammation and oxidative stress, and shared lifestyle risk factors for both the cancer and CVD [6]. The increased risk for CVD has been shown among various cancers, including cancers of the breast, lung, prostate, pancreatic, hematologic, esophageal, kidney, and ovary [7,8].

Particulate matter (PM), defined as material suspended in the air in the form of minute solid particles or liquid droplets, is related to both cancers and CVD. It is currently classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC) [9,10]. It has a dose-response relationship with carcinogenesis in various cancer types [9-11]. PM is also associated with subclinical atherosclerosis [12] and increased morbidity and mortality from CVD [13,14]. The size of PM has an influence on the pathophysiology of relative diseases and is generally classified into PM<sub>10</sub> (<10  $\mu\text{m}$  diameter); which is further subdivided into PM<sub>2.5-10</sub> (2.5-10  $\mu\text{m}$ ), PM<sub>2.5</sub> (<2.5  $\mu\text{m}$ ), and ultrafine (<0.1  $\mu\text{m}$ ) [15]. PM less than 10  $\mu\text{m}$  can deposit in airways and lungs, while the finest particles can reach the alveoli, enter the bloodstream, and cause systemic inflammation. The harmful effects of PM among people with preexisting diseases such as CVD, respiratory diseases, and diabetes is well known [16] however, there is scarce evidence among cancer survivors.

Exposure to PM affects short-term survival of patients with lung and liver cancers [17,18] as well as long-term survival of patients with breast cancer [19]. Although former investigators speculated that PM affects cancer progression and leads to poor outcomes, cardiovascular morbidity and mortality due to PM has not yet been studied among cancer survivors.

Using data from the Korean National Health Insurance Service (NHIS), we assessed the effects of PM concentration and diameter on the incidence of CVD among patients with 5-year survival following their cancer diagnosis.

## 2. Experimental Section

### 2.1. Study population

The Korean NHIS provides mandatory health insurance for all citizens [20] covering various health services including outpatient and inpatient department visits, pharmaceutical prescriptions, surgical procedures, and procedural and laboratory examinations. All citizens aged  $\geq 40$  years are eligible for a biannual health screening exam that includes a self-reported questionnaire on their past medical history, lifestyle behaviors, anthropometric measurements including height and weight, blood pressure, and blood and urine laboratory examinations [21]. The NHIS provides some of the data from these services for research purposes and numerous epidemiological studies have used the data previously. Its validity is described in detail elsewhere [20-22].

A total of 46,334 patients from three metropolitan areas in South Korea, newly diagnosed with cancer in 2006, survived until 2011. We excluded 544 patients who were aged <20 years at diagnosis, 2,252 patients who had missing values for covariates, and 2,639 patients who were diagnosed with CVD prior to the index date from further analyses. The final study population consisted of 40,899 cancer patients who had survived for more than 5 years after initial diagnosis. Starting from the index date of 1 January 2012, all subjects were followed-up until the date of a CVD event, death, or 31 December 2017, whichever came earliest.

### 2.2. Ethical considerations

This study was approved by the Seoul National University Institutional Review Board (IRB number: E-1905-148-1035). The requirement for informed consent was waived by the review board as the NHIS database is anonymized with use of its data guided by strict confidentiality guidelines.

### 2.3. Key variables

Information on PM concentration and size was obtained from the Air Korea database which includes data on yearly average PM<sub>2.5</sub> and PM<sub>10</sub> levels for the administrative district areas in South Korea. The Air Korea database collects daily PM levels using more than 300 atmospheric monitoring sites distributed across the entire country. PM<sub>2.5</sub> levels were available for three metropolitan cities (Seoul, Busan, and Incheon) starting from 2008 allowing us to determine the average PM level

exposure from 2008-2011 for people residing in these three metropolitan cities which contain 50 administrative districts and reside over a third of the entire population of South Korea. PM2.5-10 levels were calculated by subtracting the PM10 levels from the PM2.5 levels. The average PM2.5, PM10, and PM2.5-10 levels were linked with the residential district codes for each participant, after which the participants were divided into quintiles of PM levels.

Cancer survivors were defined as participants newly diagnosed with cancer in 2006 who survived until 2011 (at least 5 years). Cancer was defined as having a cancer diagnosis code (ICD-10: C00-C99) and the critical condition code for cancer as was defined in a previous study [23]. The primary outcome, CVD, was defined as any hospitalization for coronary heart disease (CHD) or stroke for  $\geq 2$  days. Upon admission, the attending physicians are required to record a primary diagnosis for each patient according to the International Classification of Diseases, Tenth Revision codes. The ICD-10 codes for CHD (I20-I25) and stroke (I60-I69) were derived from the American Heart Association guidelines [24].

We considered the following covariates in the multivariate analysis: age (continuous, years); sex (categorical: men and women); household income (categorical: 1st, 2nd, 3rd, and 4th quintiles); area of residence (categorical: Seoul, Busan, and Incheon); and Charlson comorbidity index (continuous). Household income was derived from the insurance premium. The algorithm for calculating Charlson comorbidity index values from health claims data was adopted from a previous study [25].

2.4. Statistical analysis

Differences in the distribution of covariates according to quintiles of PM2.5 or PM10 levels were determined using the Chi-squared test for categorical variables and the analysis of variance for continuous variables. The adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CVD, CHD, and stroke risk were calculated using the multivariate Cox proportional hazards regression. Subjects within the lowest levels of PM2.5, PM10, and PM2.5-10 were used as the reference group. The association of PM2.5 levels on CVD risk were determined according to the cancer types which included lung, breast, liver, stomach, colorectal, kidney, bladder, prostate, and smoking-related and obesity-related cancers. Smoking-related cancers included malignancies from the head and neck, esophagus, stomach, colorectum, liver, pancreas larynx, trachea, bronchus and lung, bladder, kidney, and acute myeloid leukemia [26]. Obesity-related cancers included breast, cervical, endometrial, uterine, colon, liver, gallbladder, pancreas, kidney, and esophageal cancers [27].

Statistical significance was determined as having a p-value  $<0.05$  in a two-sided test. All data collection and statistical analyses were conducted using SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC, USA).

3. Results

3.1. Patient characteristics

Table 1 shows the characteristics of the study population. The number of subjects residing in the 1st, 2nd, 3rd, 4th, and 5th quintiles of PM2.5 levels were 8,206, 8,100, 7,837, 9,087, and 7,669, respectively. The range of PM2.5 levels in order of increasing quintile groups were 19.8-23.9, 24.1-25.3, 25.4-26.4, 26.5-27.8, and 28.2-33.8  $\mu\text{g}/\text{m}^3$ . Participants residing in areas with the highest PM2.5 levels were younger, had higher household income, and had less comorbidities (all  $p<0.001$ ). The number of participants within the 1st, 2nd, 3rd, 4th, and 5th quintiles of PM10 levels were 8,891, 7,210, 7,984, 8,519, and 8,295, respectively. The range of PM10 levels in order of increasing quintile groups were 35.5-49.1, 49.7-50.4, 50.4-52.6, 52.7-54.1, and 54.4-61.9  $\mu\text{g}/\text{m}^3$ . Compared to those residing in the lowest levels of PM10, cancer survivors residing in the highest levels of PM10 were younger, had higher household income, and had less comorbidities (all  $p<0.001$ ).

Table 1. Descriptive characteristics of the study population.

	Particulate matter, quintiles					p value
	1 <sup>st</sup> (lowest)	2 <sup>nd</sup>	3 <sup>rd</sup>	4 <sup>th</sup>	5 <sup>th</sup> (highest)	

PM <sub>2.5</sub>						
Number of participants	8,206	8,100	7,837	9,087	7,669	
Range, µg/m <sup>3</sup>	19.8-23.9	24.1-25.3	25.4-26.4	26.5-27.8	28.2-33.8	
Age, years, mean (SD)	59.1 (13.0)	59.8 (13.3)	59.4 (13.2)	59.5 (12.9)	57.9 (13.2)	<0.001
Sex, N (%)						
Men	3,094 (37.7)	2,945 (36.4)	2,988 (38.1)	3,589 (39.5)	2,862 (37.3)	<0.001
Women	5,112 (62.3)	5,155 (63.6)	4,849 (61.9)	5,498 (60.5)	4,807 (62.7)	
Income, quartiles, N (%)						
1 <sup>st</sup> (highest)	3,821 (46.6)	3,643 (45.0)	4,148 (52.9)	4,206 (46.3)	3,064 (40.0)	<0.001
2 <sup>nd</sup>	1,669 (20.3)	1,616 (20.0)	1,391 (17.8)	1,861 (20.5)	1,780 (23.2)	
3 <sup>rd</sup>	1,091 (13.3)	1,110 (13.7)	986 (12.6)	1,201 (13.2)	1,184 (15.4)	
4 <sup>th</sup> (lowest)	1,625 (19.8)	1,731 (21.4)	1,312 (16.7)	1,819 (20.0)	1,641 (21.4)	
Charlson comorbidity index, N (%)						
1	1,711 (21.0)	1,609 (19.9)	1,508 (19.2)	1,815 (20.0)	1,714 (22.4)	<0.001
2	2,676 (32.6)	2,547 (31.4)	2,684 (34.3)	2,858 (31.5)	2,470 (32.2)	
≥3	3,808 (46.4)	3,944 (48.7)	3,645 (46.5)	4,414 (48.6)	3,485 (45.4)	
PM <sub>10</sub>						
Number of participants	8,891	7,210	7,984	8,519	8,295	
Range, µg/m <sup>3</sup>	35.5-49.1	49.7-50.4	50.4-52.6	52.7-54.1	54.4-61.9	
Age, years, mean (SD)	59.7 (13.1)	58.8 (13.0)	59.7 (13.1)	58.8 (13.2)	58.7 (13.2)	<0.001
Sex, N (%)						
Men	3,344 (37.6)	2,700 (37.5)	3,016 (37.8)	3,259 (38.3)	3,159 (38.1)	0.824
Women	5,547 (62.4)	4,510 (62.6)	4,968 (62.2)	5,260 (61.7)	5,136 (61.9)	
Income, quartiles, N (%)						
1 <sup>st</sup> (highest)	3,921 (44.1)	3,575 (49.6)	3,776 (47.3)	4,129 (48.5)	3,481 (42.0)	<0.001
2 <sup>nd</sup>	1,856 (20.9)	1,337 (18.5)	1,616 (20.2)	1,674 (19.7)	1,834 (22.1)	
3 <sup>rd</sup>	1,219 (13.7)	988 (13.7)	1,054 (13.2)	1,112 (13.1)	1,199 (14.5)	
4 <sup>th</sup> (lowest)	1,895 (21.3)	1,310 (18.2)	1,538 (19.3)	1,604 (18.8)	1,781 (21.5)	
Charlson comorbidity index, N (%)						
1	1,878 (21.1)	1,407 (19.5)	1,629 (20.4)	1,648 (19.3)	1,806 (21.8)	<0.001
2	2,718 (30.6)	2,448 (34.0)	2,598 (32.5)	2,857 (33.5)	2,614 (31.5)	
≥3	4,295 (48.3)	3,355 (46.5)	3,757 (47.1)	4,014 (47.1)	3,875 (46.7)	

Particulate matter levels determined by 4-year average levels during 2008-2011.

*p* value calculated by Chi-squared test for categorical variables and analysis of variance for continuous variables.

Acronyms: PM, particulate matter; SD, standard deviation; N, number of participants.

### 3.2. Association of PM levels with CVD risk

The association of PM<sub>2.5</sub> levels with CVD risk is shown in Table 2. Compared to participants within the lowest quintile of PM<sub>2.5</sub>, those in the highest PM<sub>2.5</sub> quintile group were at higher risk for CVD (aHR 1.31, 95% CI 1.07-1.59). Similarly, participants residing in the highest PM<sub>2.5</sub> areas were at higher risk for CHD (aHR 1.47, 95% CI 1.10-1.95) compared to those within the lowest quintile. Moreover, there was a risk-increasing trend for CVD and CHD (*p* for trend 0.011) according to higher groups of PM<sub>2.5</sub> quintiles. The risk for CVD according to PM<sub>10</sub> quintile levels are shown in Table 3. Compared to those within the lowest quintile of PM<sub>10</sub>, cancer survivors with the highest exposure to PM<sub>10</sub> did not have a higher risk for CVD (aHR 1.04, 95% CI 0.89-1.21), CHD (aHR 1.09, 95% CI 0.87-1.36), or stroke (aHR 0.99, 95% CI 0.80-1.22). Table 4 shows the association of PM<sub>2.5-10</sub> levels with CVD risk among cancer survivors. Compared to subjects within the lowest quintile of PM<sub>2.5-10</sub>, participants residing in the highest quintile of PM<sub>2.5-10</sub> did not have higher risk for CVD (aHR 1.04, 95% CI 0.90-1.20), CHD (aHR 1.02, 95% CI 0.83-1.25), and stroke (aHR 1.06, 95% CI 0.87-1.29). Finally, the risk of CVD among survivors from lung, breast, liver, stomach, colorectal, kidney, bladder, prostate, smoking-related, and obesity-related cancers according to PM<sub>2.5</sub> levels is shown in Table 5. There was a tendency towards increased CVD risk for higher PM<sub>2.5</sub> levels, although the results were not significant due to the reduced number of participants and statistical power.

**Table 2.** Hazard ratios for cardiovascular disease according to post-diagnosis PM<sub>2.5</sub> levels among 5-year cancer survivors.

	PM <sub>2.5</sub> , quintiles					<i>p</i> for trend
	1 <sup>st</sup> (lowest)	2 <sup>nd</sup>	3 <sup>rd</sup>	4 <sup>th</sup>	5 <sup>th</sup> (highest)	
Cardiovascular disease						
Events	359	329	325	349	365	
Person-years	45,317	44,937	43,626	50,065	42,207	
aHR (95% CI)	1.00 (reference)	1.02 (0.86-1.19)	1.06 (0.90-1.24)	1.11 (0.96-1.27)	1.31 (1.07-1.59)	0.011
Coronary heart disease						
Events	158	133	133	202	166	
Person-years	45,317	44,937	43,626	50,065	42,207	
aHR (95% CI)	1.00 (reference)	1.06 (0.83-1.36)	1.11 (0.86-1.42)	1.19 (0.96-1.46)	1.47 (1.10-1.95)	0.011
Stroke						
Events	201	196	192	237	199	
Person-years	45,317	44,937	43,626	50,065	42,207	
aHR (95% CI)	1.00 (reference)	0.98 (0.79-1.21)	1.02 (0.83-1.26)	1.06 (0.87-1.26)	1.18 (0.91-1.55)	0.257

Particulate matter levels determined by 4-year average levels during 2008-2011.

Adjusted hazard ratio calculated by Cox proportional hazards regression analysis after adjustments for age, sex, household income, area of residence, and Charlson comorbidity index.

Acronyms: PM, particulate matter; aHR, adjusted hazard ratio; CI, confidence interval.

**Table 3.** Hazard ratios for cardiovascular disease according to post-diagnosis PM<sub>10</sub> levels among 5-year cancer survivors.

	PM <sub>10</sub> , quintiles					<i>p</i> for trend
	1 <sup>st</sup> (lowest)	2 <sup>nd</sup>	3 <sup>rd</sup>	4 <sup>th</sup>	5 <sup>th</sup> (highest)	
Cardiovascular disease						
Events	394	267	384	387	385	
Person-years	49,015	40,138	44,160	47,328	45,510	
aHR (95% CI)	1.00 (reference)	0.98 (0.83-1.15)	1.18 (1.02-1.36)	1.21 (1.05-1.41)	1.04 (0.89-1.21)	0.078
Coronary heart disease						
Events	181	105	162	157	185	
Person-years	49,015	40,138	44,160	47,328	45,510	
aHR (95% CI)	1.00 (reference)	0.88 (0.69-1.13)	1.14 (0.92-1.42)	1.18 (0.94-1.48)	1.09 (0.87-1.36)	0.111
Stroke						
Events	213	162	222	228	200	
Person-years	49,015	40,138	44,160	47,328	45,510	
aHR (95% CI)	1.00 (reference)	1.05 (0.85-1.30)	1.20 (0.99-1.46)	1.24 (1.02-1.51)	0.99 (0.80-1.22)	0.348

Particulate matter levels determined by 4-year average levels during 2008-2011.

Adjusted hazard ratio calculated by Cox proportional hazards regression analysis after adjustments for age, sex, household income, area of residence, and Charlson comorbidity index.

Acronyms: PM, particulate matter; aHR, adjusted hazard ratio; CI, confidence interval.

**Table 4.** Hazard ratios for cardiovascular disease according to post-diagnosis PM<sub>2.5-10</sub> levels among 5-year cancer survivors.

	PM <sub>2.5-10</sub> , quintiles					<i>p</i> for trend
	1 <sup>st</sup> (lowest)	2 <sup>nd</sup>	3 <sup>rd</sup>	4 <sup>th</sup>	5 <sup>th</sup> (highest)	
Cardiovascular disease						
Events	419	326	286	423	363	
Person-years	46,989	43,996	42,215	50,648	42,304	
aHR (95% CI)	1.00 (reference)	1.03 (0.88-1.20)	0.94 (0.80-1.11)	1.10 (0.95-1.27)	1.04 (0.90-1.20)	0.361
Coronary heart disease						
Events	203	128	116	178	167	
Person-years	46,989	43,996	42,215	50,648	42,304	
aHR (95% CI)	1.00 (reference)	0.92 (0.72-1.17)	0.87 (0.68-1.11)	1.03 (0.82-1.28)	1.02 (0.83-1.25)	0.576
Stroke						
Events	216	198	170	245	196	
Person-years	46,989	43,996	42,215	50,648	42,304	
aHR (95% CI)	1.00 (reference)	1.11 (0.90-1.37)	1.00 (0.80-1.24)	1.16 (0.95-1.41)	1.06 (0.87-1.29)	0.468

Particulate matter levels determined by 4-year average levels during 2008-2011.  
PM<sub>2.5-10</sub>: particulate matter with sizes between 2.5 and 10 µm.  
Adjusted hazard ratio calculated by Cox proportional hazards regression analysis after adjustments for age, sex, household income, area of residence, and Charlson comorbidity index.  
Acronyms: PM, particulate matter; aHR, adjusted hazard ratio; CI, confidence interval.



**Table 5.** Association of post-diagnosis PM<sub>2.5</sub> levels with cardiovascular disease risk among 5-year cancer survivors according to cancer types.

	PM <sub>2.5</sub> , quintiles					<i>p</i> for trend
	1 <sup>st</sup> (lowest)	2 <sup>nd</sup>	3 <sup>rd</sup>	4 <sup>th</sup>	5 <sup>th</sup> (highest)	
Lung cancer						
Events	12	9	10	9	12	
Person-years	841	799	846	946	783	
aHR (95% CI)	1.00 (reference)	0.71 (0.29-1.73)	0.83 (0.34-1.98)	0.79 (0.33-1.89)	2.46 (0.93-6.52)	0.389
Breast cancer						
Events	34	30	41	36	48	
Person-years	8,013	8,016	7,250	8,591	7,461	
aHR (95% CI)	1.00 (reference)	1.08 (0.63-1.86)	1.60 (0.97-2.65)	1.04 (0.65-1.66)	2.25 (1.32-3.85)	0.045
Liver cancer						
Events	14	9	10	5	12	
Person-years	1,006	962	996	1,171	853	
aHR (95% CI)	1.00 (reference)	0.90 (0.35-2.31)	1.04 (0.41-2.63)	0.34 (0.12-0.96)	0.84 (0.23-2.98)	0.107
Stomach cancer						
Events	79	70	77	90	81	
Person-years	7,618	7,601	6,931	8,867	7,624	
aHR (95% CI)	1.00 (reference)	0.96 (0.68-1.35)	1.14 (0.81-1.60)	0.99 (0.73-1.35)	1.33 (0.88-2.02)	0.379
Colorectal cancer						
Events	81	70	54	86	62	
Person-years	6,160	6,007	5,630	6,466	5,588	
aHR (95% CI)	1.00 (reference)	0.88 (0.62-1.24)	0.77 (0.53-1.12)	1.00 (0.74-1.36)	1.17 (0.74-1.86)	0.630
Kidney cancer						
Events	13	6	6	15	11	
Person-years	1,154	1,079	1,070	1,182	947	
aHR (95% CI)	1.00 (reference)	0.50 (0.18-1.38)	0.55 (0.20-1.54)	1.07 (0.50-2.28)	1.65 (0.60-4.56)	0.301
Bladder cancer						
Events	13	23	13	29	19	
Person-years	1,117	1,062	1,061	1,518	966	
aHR (95% CI)	1.00 (reference)	2.86 (1.34-6.12)	1.62 (0.70-3.75)	1.77 (0.91-3.43)	2.44 (1.00-5.95)	0.210
Prostate cancer						
Events	20	17	21	28	15	
Person-years	1,115	1,073	1,502	1,276	737	
aHR (95% CI)	1.00 (reference)	0.86 (0.43-1.69)	0.83 (0.43-1.59)	1.26 (0.70-2.26)	1.23 (0.52-2.90)	0.304
Smoking-related cancer						
Events	226	201	185	253	218	
Person-years	19,067	18,508	17,502	21,442	17,977	
aHR (95% CI)	1.00 (reference)	0.99 (0.81-1.22)	0.99 (0.80-1.22)	1.00 (0.84-1.20)	1.34 (1.04-1.73)	0.201
Obesity-related cancer						
Events	166	137	133	174	161	
Person-years	21,160	21,073	18,987	22,623	19,772	
aHR (95% CI)	1.00 (reference)	0.88 (0.69-1.13)	0.97 (0.76-1.24)	0.98 (0.79-1.21)	1.33 (0.99-1.78)	0.209

Particulate matter levels determined by 4-year average levels during 2008-2011.

Smoking-related cancer included head and neck, esophagus, stomach, colorectum, liver, pancreas larynx, trachea, bronchus and lung, bladder, kidney cancer, and acute myeloid leukemia.

Obesity-related cancer included breast, cervical, endometrial, uterine, colon, liver, gallbladder, pancreas, kidney, and esophageal cancer.

Adjusted hazard ratio calculated by Cox proportional hazards regression analysis after adjustments for age, sex, household income, area of residence, and Charlson comorbidity index.

Acronyms: PM, particulate matter; aHR, adjusted hazard ratio; CI, confidence interval.

#### 4. Discussion

In the three-metropolitan areas with over 40,000 cancer survivors, long-term exposure to PM was associated with increased CVD incidence. To our knowledge, this is the first study to identify an increasing effect of PM<sub>2.5</sub> levels on CVD in long-term cancer survivors. The higher the concentration of PM<sub>2.5</sub>, the more incident CVD, confirming the concentration-response relationship. The hazard ratio for CVD increased from PM<sub>2.5</sub> concentrations of 28.2 µg/m<sup>3</sup>.

In previous studies, PM<sub>2.5</sub> has been reported to be the most pathogenic for CVD in the general population, with PM<sub>2.5-10</sub> and PM<sub>10</sub> levels having inconsistent results [15,28,29]. Our study also

showed similar results. We found that a yearly average concentration of  $28.2 \mu\text{g}/\text{m}^3$ , which is above the yearly PM<sub>2.5</sub> regulation guideline in South Korea ( $15 \mu\text{g}/\text{m}^3$ ), US ( $12 \mu\text{g}/\text{m}^3$ ), European Union ( $25 \mu\text{g}/\text{m}^3$ ), and Japan ( $15 \mu\text{g}/\text{m}^3$ ) [30], increased the risk for CVD.

In the general population, an increase in the PM<sub>2.5</sub> concentration by  $10 \mu\text{g}/\text{m}^3$  was associated with an increase in the number of hospital admissions for coronary artery disease, arrhythmias, heart failure, cerebrovascular disease, and peripheral artery disease [31]. The susceptible population included children, older adults, those that were obese, had low socioeconomic status (SES), and specific genetic factors [32]. Unlike traditional Framingham risk factors, women were more susceptible to CVD when exposed to PM<sub>2.5</sub> than men probably due to their smaller coronary arteries and micro vessels [33-36].

In addition to those risk factors, cancer survivors may be more susceptible to the harmful effects of PM. They are often asymptomatic but several times higher prevalence of CVD compared with the Framingham Heart Study population [37]. Chemotherapy agents for cancer patients have several vascular complications including endothelial dysfunction, capillary rarefaction, vascular remodeling, oxidative stress, platelet activation, thrombosis, and vasospasm [38]. In addition, radiotherapy impairs diastolic and systolic function [39]. The time-lapse between chemotherapy and radiotherapy and incident CVD can be very long, lasting even more than 10 years [40,41].

In the present study, breast and bladder cancer survivors were the most affected by PM<sub>2.5</sub> which is consistent with a previous study [19]. PM seems to have a greater influence on CVD-susceptible cancers of all kind. In the previous study, endometrial, breast, melanoma, prostate, and urinary bladder cancer were susceptible among cancers in 28 sites [42]. Breast cancer survivors treated with taxanes, vascular endothelial growth factor (VEGF) inhibitor, and hormonal agents experience increased thrombotic events, severe hypertension, and heart failure [38,39].

The relationship between bladder cancer and the PM remains controversial. Environmental and socioeconomic factors are known to affect bladder cancer mortality [43]. Those engaged in occupations such as taxi driver, truck driver, or street vendor are highly exposed to air pollution and have been reported to be at increased risk for bladder cancers [44]. However, there was no association reported between PM<sub>2.5</sub> concentrations and bladder cancer incidence in 15 European cohort studies and one Spanish study [45,46]. The relationship between non-cancer mortality and PM has scarce evidence for bladder cancers. Patients with bladder cancers had high to no risk for CVD in the previous studies [7,42]. In our long-term bladder cancer survivors, the concentration of  $24.1$ - $25.3$  and  $28.2$ - $33.8 \mu\text{g}/\text{m}^3$  of PM<sub>2.5</sub> was associated with CVD. Further research in other large-scale populations is needed.

In the present study, there was no association between PM concentration and stroke in cancer survivors. Both hemorrhagic and ischemic stroke risk were increased in cancer patients [47,48] even after 10 years of surviving [49] in previous studies. This phenomenon may need to be investigated further.

Our study has several limitations. First, operationally defined CVD may be incorrectly coded. Unstable angina is one of the most up coded conditions [50] and there is also the possibility that patients with multiple CVD could be down coded should the doctor not have recorded all ICD codes for multiple complex conditions. However, the operational diagnosis was validated and had been widely used in previous studies [51,52]. Second, ischemic and hemorrhagic strokes could not be differentiated due to lack of data. Third, the study population was from three metropolitan cities, so the results may not be generalizable to rural areas. Fourth, the residential areas and areas where the population spends most of their time (such as the workplace) may be different. Fifth, the individual CVD risk factors (smoking, diet, alcohol use, access to care, obesity, blood pressure, lipid profile, and family history) were not identified, although non-smokers had a greater risk for air-pollution related disease than current smokers in the previous study [53].

## 5. Conclusions

We found that higher levels of PM<sub>2.5</sub> were associated with increased CVD among cancer survivors, implying that cancer survivors are a vulnerable group when exposed to PM. Among the



various cancer types, breast and bladder cancer survivors were the most affected. Future studies will be needed to evaluate the impact of PM exposure reduction among cancer survivors.

#### Author Contributions:

SM Park had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis; Study concept and design: SM Park; Acquisition of data: S Choi, K Kim, SM Park; Analysis and interpretation of data: S Choi, KH Kim, K Kim, J Chang, SM Kim, SR Kim, Y Cho, G Lee, JS Son, SM Park; Drafting of the manuscript: S Choi, KH Kim, SM Park; Critical revision of the manuscript: S Choi, KH Kim, K Kim, J Chang, SM Kim, SR Kim, Y Cho, G Lee, JS Son, SM Park; Statistical analysis: S Choi; Administrative, technical, or material support: K Kim, SM Kim

**Funding:** This research was supported by Korea Centers for Disease Control and Prevention (grant number: 2019060E80A-00).

**Acknowledgments:** In this section you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

**Conflicts of Interest:** None of the authors reported disclosures.

#### References

1. Jung, K.-W.; Won, Y.-J.; Kong, H.-J.; Lee, E.S. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016. *Cancer research and treatment : official journal of Korean Cancer Association* **2019**, *51*, 417-430, doi:10.4143/crt.2019.138.
2. Howlader N, N.A., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. *SEER Cancer Statistics Review, 1975-2016*; National Cancer Institute. Bethesda, MD: 2019.
3. Korea Central Cancer Registry, N.C.C. *Annual report of cancer statistics in Korea in 2016*; Ministry of Health and Welfare: 2018.
4. Miller, K.D.; Siegel, R.L.; Lin, C.C.; Mariotto, A.B.; Kramer, J.L.; Rowland, J.H.; Stein, K.D.; Alteri, R.; Jemal, A. Cancer treatment and survivorship statistics, 2016. *CA: A Cancer Journal for Clinicians* **2016**, *66*, 271-289, doi:10.3322/caac.21349.
5. Sturgeon, K.M.; Deng, L.; Bluethmann, S.M.; Zhou, S.; Trifiletti, D.M.; Jiang, C.; Kelly, S.P.; Zaorsky, N.G. A population-based study of cardiovascular disease mortality risk in US cancer patients. *European Heart Journal* **2019**, 10.1093/eurheartj/ehz766, doi:10.1093/eurheartj/ehz766.
6. Koene, R.J.; Prizment, A.E.; Blaes, A.; Konety, S.H. Shared risk factors in cardiovascular disease and cancer. *Circulation* **2016**, *133*, 1104-1114.
7. Armenian, S.H.; Xu, L.; Ky, B.; Sun, C.; Farol, L.T.; Pal, S.K.; Douglas, P.S.; Bhatia, S.; Chao, C. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. *Journal of Clinical Oncology* **2016**, *34*, 1122-1130.
8. Strongman, H.; Gadd, S.; Matthews, A.; Mansfield, K.E.; Stanway, S.; Lyon, A.R.; dos-Santos-Silva, I.; Smeeth, L.; Bhaskaran, K. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. *The Lancet* **2019**, *394*, 1041-1054, doi:10.1016/S0140-6736(19)31674-5.
9. Loomis, D.; Grosse, Y.; Lauby-Secretan, B.; Ghissassi, F.E.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Baan, R.; Mattock, H.; Straif, K. The carcinogenicity of outdoor air pollution. *The Lancet Oncology* **2013**, *14*, 1262-1263, doi:[https://doi.org/10.1016/S1470-2045\(13\)70487-X](https://doi.org/10.1016/S1470-2045(13)70487-X).

10. International Agency for Research on Cancer. IARC: *Outdoor air pollution a leading environmental cause of cancer deaths*; International Agency for Research on Cancer: 2011.
11. Hamra, G.B.; Guha, N.; Cohen, A.; Laden, F.; Raaschou-Nielsen, O.; Samet, J.M.; Vineis, P.; Forastiere, F.; Saldiva, P.; Yorifuji, T., et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. *Environmental health perspectives* **2014**, *122*, 906-911, doi:10.1289/ehp/1408092.
12. Akintoye, E.; Shi, L.; Obaitan, I.; Olusunmade, M.; Wang, Y.; Newman, J.D.; Dodson, J.A. Association between fine particulate matter exposure and subclinical atherosclerosis: A meta-analysis. *Eur J Prev Cardiol* **2016**, *23*, 602-612, doi:10.1177/2047487315588758.
13. Nishiwaki, Y.; Michikawa, T.; Takebayashi, T.; Nitta, H.; Iso, H.; Inoue, M.; Tsugane, S.; Japan Public Health Center-based Prospective Study, G. Long-term exposure to particulate matter in relation to mortality and incidence of cardiovascular disease: the JPHC Study. *J Atheroscler Thromb* **2013**, *20*, 296-309, doi:10.5551/jat.15347.
14. Pope, C.A., 3rd; Burnett, R.T.; Krewski, D.; Jerrett, M.; Shi, Y.; Calle, E.E.; Thun, M.J. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. *Circulation* **2009**, *120*, 941-948, doi:10.1161/CIRCULATIONAHA.109.857888.
15. Esworthy, R. Air quality: EPA's 2013 changes to the particulate matter (PM) standard.
16. Inoue, K.; Takano, H. Particulate matter-induced health effects: who is susceptible? *Environ Health Perspect* **2011**, *119*, A285, doi:10.1289/ehp.1103846.
17. Eckel, S.P.; Cockburn, M.; Shu, Y.H.; Deng, H.; Lurmann, F.W.; Liu, L.; Gilliland, F.D. Air pollution affects lung cancer survival. *Thorax* **2016**, *71*, 891-898, doi:10.1136/thoraxjnl-2015-207927.
18. Deng, H.; Eckel, S.P.; Liu, L.; Lurmann, F.W.; Cockburn, M.G.; Gilliland, F.D. Particulate matter air pollution and liver cancer survival. *International Journal of Cancer* **2017**, *141*, 744-749, doi:10.1002/ijc.30779.
19. DuPre, N.C.; Hart, J.E.; Holmes, M.D.; Poole, E.M.; James, P.; Kraft, P.; Laden, F.; Tamimi, R.M. Particulate Matter and Traffic-Related Exposures in Relation to Breast Cancer Survival. *Cancer Epidemiol Biomarkers Prev* **2019**, *28*, 751-759, doi:10.1158/1055-9965.EPI-18-0803.
20. Cheol Seong, S.; Kim, Y.Y.; Khang, Y.H.; Heon Park, J.; Kang, H.J.; Lee, H.; Do, C.H.; Song, J.S.; Hyon Bang, J.; Ha, S., et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. *Int J Epidemiol* **2017**, *46*, 799-800, doi:10.1093/ije/dyw253.
21. Lee, J.; Lee, J.S.; Park, S.H.; Shin, S.A.; Kim, K. Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. *Int J Epidemiol* **2017**, *46*, e15, doi:10.1093/ije/dyv319.
22. Seong, S.C.; Kim, Y.Y.; Park, S.K.; Khang, Y.H.; Kim, H.C.; Park, J.H.; Kang, H.J.; Do, C.H.; Song, J.S.; Lee, E.J., et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. *BMJ Open* **2017**, *7*, e016640, doi:10.1136/bmjopen-2017-016640.
23. Kim, K.; Choi, S.; Park, S.M. Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: A large cohort study. *Eur J Cancer* **2018**, *102*, 103-113, doi:10.1016/j.ejca.2018.07.008.
24. Benjamin, E.J.; Muntner, P.; Alonso, A.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Das, S.R., et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation* **2019**, *139*, e56-e528, doi:10.1161/CIR.0000000000000659.
25. Sundararajan, V.; Henderson, T.; Perry, C.; Muggivan, A.; Quan, H.; Ghali, W.A. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol* **2004**, *57*, 1288-1294, doi:10.1016/j.jclinepi.2004.03.012.
26. Choi, S.; Chang, J.; Kim, K.; Park, S.M.; Lee, K. Effect of Smoking Cessation and Reduction on the Risk of Cancer in Korean Men: A Population Based Study. *Cancer Res Treat* **2018**, *50*, 1114-1120, doi:10.4143/crt.2017.326.

27. Moore, L.L.; Chadid, S.; Singer, M.R.; Kreger, B.E.; Denis, G.V. Metabolic health reduces risk of obesity-related cancer in framingham study adults. *Cancer Epidemiol Biomarkers Prev* **2014**, *23*, 2057-2065, doi:10.1158/1055-9965.EPI-14-0240.
28. Brook, R.D.; Rajagopalan, S.; Pope III, C.A.; Brook, J.R.; Bhatnagar, A.; Diez-Roux, A.V.; Holguin, F.; Hong, Y.; Luepker, R.V.; Mittleman, M.A. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. *Circulation* **2010**, *121*, 2331-2378.
29. Dockery, D.W.; Stone, P.H. Cardiovascular risks from fine particulate air pollution. Mass Medical Soc: 2007.
30. Kim, K.H.; Kabir, E.; Kabir, S. A review on the human health impact of airborne particulate matter. *Environment international* **2015**, *74*, 136-143, doi:10.1016/j.envint.2014.10.005.
31. Dominici, F.; Peng, R.D.; Bell, M.L.; Pham, L.; McDermott, A.; Zeger, S.L.; Samet, J.M. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. *JAMA* **2006**, *295*, 1127-1134, doi:10.1001/jama.295.10.1127.
32. Sacks, J.D.; Stanek, L.W.; Luben, T.J.; Johns, D.O.; Buckley, B.J.; Brown, J.S.; Ross, M. Particulate matter-induced health effects: who is susceptible? *Environ Health Perspect* **2011**, *119*, 446-454, doi:10.1289/ehp.1002255.
33. Miller, K.A.; Siscovick, D.S.; Sheppard, L.; Shepherd, K.; Sullivan, J.H.; Anderson, G.L.; Kaufman, J.D. Long-term exposure to air pollution and incidence of cardiovascular events in women. *New England Journal of Medicine* **2007**, *356*, 447-458.
34. Pope III, C.A.; Burnett, R.T.; Thurston, G.D.; Thun, M.J.; Calle, E.E.; Krewski, D.; Godleski, J.J. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. *Circulation* **2004**, *109*, 71-77.
35. Pepine, C.J.; Kerensky, R.A.; Lambert, C.R.; Smith, K.M.; von Mering, G.O.; Sopko, G.; Bairey Merz, C.N. Some thoughts on the vasculopathy of women with ischemic heart disease. *J Am Coll Cardiol* **2006**, *47*, S30-35, doi:10.1016/j.jacc.2005.09.023.
36. Dockery, D.W.; Stone, P.H. Cardiovascular risks from fine particulate air pollution. *N Engl J Med* **2007**, *356*, 511-513, doi:10.1056/NEJMe068274.
37. Heidenreich, P.A.; Hancock, S.L.; Lee, B.K.; Mariscal, C.S.; Schnittger, I. Asymptomatic cardiac disease following mediastinal irradiation. *Journal of the American College of Cardiology* **2003**, *42*, 743-749.
38. Cameron, A.C.; Touyz, R.M.; Lang, N.N. Vascular Complications of Cancer Chemotherapy. *Can J Cardiol* **2016**, *32*, 852-862, doi:10.1016/j.cjca.2015.12.023.
39. Zamorano, J.L.; Lancellotti, P.; Rodriguez Muñoz, D.; Aboyans, V.; Asteggiano, R.; Galderisi, M.; Habib, G.; Lenihan, D.J.; Lip, G.Y.H.; Lyon, A.R., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *European Heart Journal* **2016**, *37*, 2768-2801, doi:10.1093/eurheartj/ehw211.
40. de Azambuja, E.; Ameye, L.; Diaz, M.; Vandenbossche, S.; Aftimos, P.; Hernández, S.B.; Shih-Li, C.; Delhaye, F.; Focan, C.; Cornez, N. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil-or epirubicin-based chemotherapy. *European journal of cancer* **2015**, *51*, 2517-2524.
41. Glanzmann, C.; Huguenin, P.; Lütolf, U.; Maire, R.; Jenni, R.; Gumpfenberg, V. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. *Radiotherapy and Oncology* **1994**, *30*, 43-54.
42. Sturgeon, K.M.; Deng, L.; Bluethmann, S.M.; Zhou, S.; Trifiletti, D.M.; Jiang, C.; Kelly, S.P.; Zaorsky, N.G. A population-based study of cardiovascular disease mortality risk in US cancer patients. *European Heart Journal* **2019**, *40*, 3889-3897, doi:10.1093/eurheartj/ehz766.

43. Smith, N.D.; Prasad, S.M.; Patel, A.R.; Weiner, A.B.; Pariser, J.J.; Razmaria, A.; Maene, C.; Schuble, T.; Pierce, B.; Steinberg, G.D. Bladder cancer mortality in the United States: a geographic and temporal analysis of socioeconomic and environmental factors. *The Journal of urology* **2016**, *195*, 290-296.
44. Brown, T.; Slack, R.; Rushton, L.; Group, w.t.B.O.C.B.S. Occupational cancer in Britain: Urinary tract cancers: bladder and kidney. *British journal of cancer* **2012**, *107*, S76.
45. Turner, M.C.; Gracia-Lavedan, E.; Cirac, M.; Castaño-Vinyals, G.; Malats, N.; Tardon, A.; Garcia-Closas, R.; Serra, C.; Carrato, A.; Jones, R.R., et al. Ambient air pollution and incident bladder cancer risk: Updated analysis of the Spanish Bladder Cancer Study. *International Journal of Cancer* **2019**, *145*, 894-900, doi:10.1002/ijc.32136.
46. Pedersen, M.; Stafoggia, M.; Weinmayr, G.; Andersen, Z.J.; Galassi, C.; Sommar, J.; Forsberg, B.; Olsson, D.; Oftedal, B.; Krog, N.H. Is there an association between ambient air pollution and bladder cancer incidence? Analysis of 15 European Cohorts. *European urology focus* **2018**, *4*, 113-120.
47. Zhang, R.; Liu, G.; Jiang, Y.; Li, G.; Pan, Y.; Wang, Y.; Wei, Z.; Wang, J.; Wang, Y. Acute Effects of Particulate Air Pollution on Ischemic Stroke and Hemorrhagic Stroke Mortality. *Front Neurol* **2018**, *9*, 827-827, doi:10.3389/fneur.2018.00827.
48. Yorifuji, T.; Kashima, S. Associations of particulate matter with stroke mortality: a multicity study in Japan. *J Occup Environ Med* **2013**, *55*, 768-771, doi:10.1097/JOM.0b013e3182973092.
49. Zoller, B.; Ji, J.; Sundquist, J.; Sundquist, K. Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. *Eur J Cancer* **2012**, *48*, 1875-1883, doi:10.1016/j.ejca.2012.01.005.
50. Wadhwa, R.K.; Sukul, D.; Secemsky, E.A.; Shen, C.; Gurm, H.S.; Boden, W.E.; Yeh, R.W. Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. *JAMA Internal Medicine* **2019**, *179*, 259-261, doi:10.1001/jamainternmed.2018.5124.
51. Kim, H.; Kim, S.; Han, S.; Rane, P.P.; Fox, K.M.; Qian, Y.; Suh, H.S. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. *BMC Public Health* **2019**, *19*, 1112, doi:10.1186/s12889-019-7439-0.
52. Kimm, H.; Yun, J.E.; Lee, S.-H.; Jang, Y.; Jee, S.H. Validity of the diagnosis of acute myocardial infarction in Korean national medical health insurance claims data: the Korean heart study (1). *Korean Circ J* **2012**, *42*, 10-15, doi:10.4070/kcj.2012.42.1.10.
53. Hamra, G.B.; Guha, N.; Cohen, A.; Laden, F.; Raaschou-Nielsen, O.; Samet, J.M.; Vineis, P.; Forastiere, F.; Saldiva, P.; Yorifuji, T., et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. *Environ Health Perspect* **2014**, *122*, 906-911, doi:10.1289/ehp.1408092  
10.1289/ehp/1408092.